Western tradition · GLP-1 agonist · prescription

Semaglutide (GLP-1 Agonist) 司美格鲁肽(GLP-1受体激动剂)

An FDA-approved diabetes/obesity drug backed by a genuinely strong cardiovascular-outcomes trial (SELECT) — its 'anti-aging' framing rests on small, early biomarker studies (epigenetic clocks, telomeres) that do not yet establish a longevity effect.

12ClinicalTrials.gov matched
23PubMed RCT records
10Meta-analysis records
24+PubMed records
SemaglutideKey active compound

Data definition. Matched records include all indexed medical endpoints for this intervention — not only longevity. Longevity-relevant records are screened separately and cited in the evidence summary below. Counts are matched-record volumes, not de-duplicated trials and not efficacy claims.

Origin & tradition

Not a supplement: semaglutide is a prescription GLP-1 receptor agonist, FDA-approved for type 2 diabetes (Ozempic/Rybelsus) and chronic weight management (Wegovy).

Why longevity buyers care

Key active: Semaglutide (GLP-1 receptor agonist).

Semaglutide mimics the gut hormone GLP-1, improving glycemic control and driving significant weight loss; the SELECT trial — a large, hard-outcomes RCT — showed a 20% reduction in major cardiovascular events in adults with overweight/obesity and existing cardiovascular disease, independent of diabetes status. Newer, smaller studies report reduced inflammatory markers, favorable shifts on epigenetic-aging clocks, and improved liver histology (ESSENCE trial), and animal work shows reduced cellular-senescence markers — but these are early, mechanism-level or small-pilot findings, not evidence that semaglutide extends human lifespan or healthspan beyond its established metabolic/cardiovascular benefits. Lean-mass loss alongside fat loss is a well-documented trade-off requiring resistance training and adequate protein.

Effect summary

Studied health outcomes

Editorial summary — This table is curated by hand from published research consensus, not automatically calculated from our trial database. Grades reflect our interpretation of the literature. Treat as a starting point, not a definitive verdict. See the Evidence panel below for the underlying trial and paper counts sourced directly from ClinicalTrials.gov and PubMed.
Health outcomeEffectMagnitudeGrade
Body weight↓DecreasesStrongA
Major adverse cardiovascular events (SELECT trial, overweight/obese with CVD)↓DecreasesModerateA
HbA1c / glycemic control↓DecreasesStrongA
Lean muscle mass — Documented alongside fat loss; mitigated by resistance training and adequate protein intake↓DecreasesModerateB
Epigenetic aging clocks / cellular senescence markers — Early, small pilot studies — not yet an established longevity effect↓DecreasesMinorC
Human lifespan extension — No trial designed or powered to test this→No changeNegligibleD

Grade: A = robust RCTs · B = several RCTs / meta-analysis · C = limited or mixed RCTs · D = observational or early data

Dosage guidance

How Semaglutide (GLP-1 Agonist) is typically used

Prescription medication — requires a licensed prescriber. Not a supplement.
Typical dose
Titrated from 0.25 mg up to 1–2.4 mg/week (weight-management dosing; diabetes dosing differs)
Form
prescription only — subcutaneous injection (weekly) or oral tablet (Rybelsus, daily)
Timing
once weekly (injection) or once daily (oral), per prescribing physician; dose titrated slowly to manage GI side effects

PRESCRIPTION ONLY. FDA-approved for type 2 diabetes and chronic weight management — not for general anti-aging use. Common side effects: nausea, GI upset. Requires resistance training and adequate protein to offset lean-mass loss. Discontinuation is typically followed by substantial weight regain unless lifestyle changes are sustained.

Informational only — not a prescription or personalised medical advice. Consult a qualified clinician before starting any supplement or medication.

Evidence summary

What the research actually says

56Evidence confidence
Human RCT evidence23 randomized controlled trials · 10 meta-analyses / systematic reviews

Large hard-outcomes RCT (SELECT) for cardiovascular events; longevity/aging-biomarker evidence is early and small-scale

Semaglutide mimics the gut hormone GLP-1, improving glycemic control and driving significant weight loss; the SELECT trial — a large, hard-outcomes RCT — showed a 20% reduction in major cardiovascular events in adults with overweight/obesity and existing cardiovascular disease, independent of diabetes status. Newer, smaller studies report reduced inflammatory markers, favorable shifts on epigenetic-aging clocks, and improved liver histology (ESSENCE trial), and animal work shows reduced cellular-senescence markers — but these are early, mechanism-level or small-pilot findings, not evidence that semaglutide extends human lifespan or healthspan beyond its established metabolic/cardiovascular benefits. Lean-mass loss alongside fat loss is a well-documented trade-off requiring resistance training and adequate protein.

12registered clinical trials reference this intervention
    3selected from 24+ PubMed papers (longevity / aging angle)
    Key active: Semaglutide (GLP-1 receptor agonist).

    According to PubMed and ClinicalTrials.gov: trial counts from ClinicalTrials.gov, peer-reviewed literature from PubMed. Counts auto-refresh weekly; last checked 2026-11-16. They include trials across many endpoints, not only longevity.

    Informational only — not medical advice, a treatment claim, or a substitute for a qualified clinician. Evidence strength varies; we show mixed and null results on purpose.

    Suppliers

    No Semaglutide (GLP-1 Agonist) suppliers listed yet

    Tell us what you need and we will source suppliers for you.

    Request sourcing help